We expect revenue/Adj.PAT to grow at 14%/42% CAGR over FY18-20E driven by expected pick-up in US sales and key speciality & generic launches. Given improved visibility for key drug launches in the US post Halol plant resolution, increased spend on specialty business and expected recovery in India business, we change our rating to HOLD' from SELL'. Our revised target price stands at Rs597 based on 23x FY20E PE. Weak US and subdued India sales drags revenue Sun Pharma reported 2% YoY decline in net revenue in Q4FY18 due to weak US sales which declined by...